X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
82
PharmaCompass offers a list of Imatinib Mesylate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Imatinib Mesylate manufacturer or Imatinib Mesylate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Imatinib Mesylate manufacturer or Imatinib Mesylate supplier.
PharmaCompass also assists you with knowing the Imatinib Mesylate API Price utilized in the formulation of products. Imatinib Mesylate API Price is not always fixed or binding as the Imatinib Mesylate Price is obtained through a variety of data sources. The Imatinib Mesylate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Imatinib Mesylate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Imatinib Mesylate, including repackagers and relabelers. The FDA regulates Imatinib Mesylate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Imatinib Mesylate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Imatinib Mesylate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Imatinib Mesylate supplier is an individual or a company that provides Imatinib Mesylate active pharmaceutical ingredient (API) or Imatinib Mesylate finished formulations upon request. The Imatinib Mesylate suppliers may include Imatinib Mesylate API manufacturers, exporters, distributors and traders.
click here to find a list of Imatinib Mesylate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Imatinib Mesylate DMF (Drug Master File) is a document detailing the whole manufacturing process of Imatinib Mesylate active pharmaceutical ingredient (API) in detail. Different forms of Imatinib Mesylate DMFs exist exist since differing nations have different regulations, such as Imatinib Mesylate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Imatinib Mesylate DMF submitted to regulatory agencies in the US is known as a USDMF. Imatinib Mesylate USDMF includes data on Imatinib Mesylate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Imatinib Mesylate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Imatinib Mesylate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Imatinib Mesylate Drug Master File in Japan (Imatinib Mesylate JDMF) empowers Imatinib Mesylate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Imatinib Mesylate JDMF during the approval evaluation for pharmaceutical products. At the time of Imatinib Mesylate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Imatinib Mesylate suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Imatinib Mesylate Drug Master File in Korea (Imatinib Mesylate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Imatinib Mesylate. The MFDS reviews the Imatinib Mesylate KDMF as part of the drug registration process and uses the information provided in the Imatinib Mesylate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Imatinib Mesylate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Imatinib Mesylate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Imatinib Mesylate suppliers with KDMF on PharmaCompass.
A Imatinib Mesylate CEP of the European Pharmacopoeia monograph is often referred to as a Imatinib Mesylate Certificate of Suitability (COS). The purpose of a Imatinib Mesylate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Imatinib Mesylate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Imatinib Mesylate to their clients by showing that a Imatinib Mesylate CEP has been issued for it. The manufacturer submits a Imatinib Mesylate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Imatinib Mesylate CEP holder for the record. Additionally, the data presented in the Imatinib Mesylate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Imatinib Mesylate DMF.
A Imatinib Mesylate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Imatinib Mesylate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Imatinib Mesylate suppliers with CEP (COS) on PharmaCompass.
A Imatinib Mesylate written confirmation (Imatinib Mesylate WC) is an official document issued by a regulatory agency to a Imatinib Mesylate manufacturer, verifying that the manufacturing facility of a Imatinib Mesylate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Imatinib Mesylate APIs or Imatinib Mesylate finished pharmaceutical products to another nation, regulatory agencies frequently require a Imatinib Mesylate WC (written confirmation) as part of the regulatory process.
click here to find a list of Imatinib Mesylate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Imatinib Mesylate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Imatinib Mesylate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Imatinib Mesylate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Imatinib Mesylate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Imatinib Mesylate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Imatinib Mesylate suppliers with NDC on PharmaCompass.
Imatinib Mesylate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Imatinib Mesylate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Imatinib Mesylate GMP manufacturer or Imatinib Mesylate GMP API supplier for your needs.
A Imatinib Mesylate CoA (Certificate of Analysis) is a formal document that attests to Imatinib Mesylate's compliance with Imatinib Mesylate specifications and serves as a tool for batch-level quality control.
Imatinib Mesylate CoA mostly includes findings from lab analyses of a specific batch. For each Imatinib Mesylate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Imatinib Mesylate may be tested according to a variety of international standards, such as European Pharmacopoeia (Imatinib Mesylate EP), Imatinib Mesylate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Imatinib Mesylate USP).
Market Place
